Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Treasury Shares (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Treasury Shares for 10 consecutive years, with $330622.0 as the latest value for Q4 2025.

  • Quarterly Treasury Shares fell 74.98% to $330622.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $330622.0 through Dec 2025, down 74.98% year-over-year, with the annual reading at $330622.0 for FY2025, 74.98% down from the prior year.
  • Treasury Shares for Q1 2016 was $162000.0 at Akebia Therapeutics.
  • The five-year high for Treasury Shares was $6.2 million in Q3 2025, with the low at $210000.0 in Q2 2023.
  • Average Treasury Shares over 5 years is $2.4 million, with a median of $1.7 million recorded in 2024.
  • The sharpest move saw Treasury Shares soared 685.89% in 2024, then plummeted 74.98% in 2025.
  • Over 5 years, Treasury Shares stood at $4.6 million in 2021, then rose by 24.59% to $5.7 million in 2022, then plummeted by 41.14% to $3.3 million in 2023, then crashed by 60.43% to $1.3 million in 2024, then tumbled by 74.98% to $330622.0 in 2025.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $330622.0, $6.2 million, and $476268.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.